Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients
To evaluate the patterns and treatment outcomes of pyrotinib plus vinorelbine in the real world.
Breast Cancer
PFS, Progression free survival, 6 weeks|Adverse events, Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0), 6 weeks
To evaluate the patterns and treatment outcomes of pyrotinib plus vinorelbine in the real world.